The global ADME toxicology testing market size was valued at USD 9.11 billion in 2020 and is anticipated to reach USD 17.8 billion by 2028, expanding at a CAGR of 11.3% during the forecast period, 2021–2028. The growth of the market is attributed to the increased investments in the discovery of newer technologies for toxicity testing.
ADME toxicity testing is primarily used to perform genetic, pharmacological, and chemical experiments that assist in various applications including drug design, drug discovery, and drug testing. Control software, various liquid-handling devices, and other detectors are used in this method to quickly identify active chemicals, genetic couplings, and other biomolecular interactions. One key reason for adopting such methods is that these devices can handle and store large amount of data quickly.
To comply with regulatory requirements, most businesses use good laboratory practice (GLP) and non-GLP testing processes to ensure the integrity and accuracy of data acquired. This measure has been widely adopted as regulatory agencies have started implementing policies to develop stricter quality control criteria for manufacturers. Several change in regulatory policies by governing bodies such as the US Food and Drug Administration (FDA) are likely to have a major impact on the market and the direction in which innovations are pursued. The FDA, for example, have directed to conduct ADME toxicity research on animals under the same disease condition as humans face, in order to draw a clear line between real-time results from the near situation and results from normal animals.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing patient awareness regarding the benefits of ADME toxicity testing is estimated to boost the market growth during the forecast period.
- Increasing rates of late-stage treatment failure, increased demand for innovative therapeutic compounds, and increased government and private sector investment in the healthcare industry around the world are anticipated to push the market growth during the forecast period.
- Government regulations and guidelines as well as the expensive cost of testing are projected to hamper the market growth.
- Lack of effective software to handle autonomous robotic arms and liquid handling systems are projected to impede the market growth during the forecast period.
- Increasing investment in research and development activities as well as technical advancements to develop innovative testing devices are projected to create lucrative opportunities for the market players.
Scope of the Report
The report on the global ADME toxicology testing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | ADME Toxicology Testing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Technology (Cell Culture, High Throughput, Molecular Imaging, and OMICS Technology), Applications (Systemic Toxicity, Renal Toxicity, Hepatotoxicity, Neurotoxicity, and Others), and Methods (Cellular Assay, Biochemical Assay, In-Silica, and Ex-vivo) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | Accelrys Inc.; Agilent Technologies, Inc.; Albany Molecular Research Inc.; Beckman Coulter Inc.; Catalent Inc.; Charles River Laboratories International Inc.; AbbVie; Actelion Pharmaceuticals; Amgen; Biocon; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; and Cipla |
Market Segment Insights
Cell culture segment is projected to account for a key market share
Based on technology, the ADME toxicology testing market is divided into cell culture, high throughput, molecular imaging, and omics technology. The cell culture segment is expected to account for a key share of the market during the forecast period due to the extreme visual findings and ability to test with the tiniest of amounts. Fluorometric imaging plate reader assays have become the most popular cell-based assays and ultra ADME toxicity testing is one of the most widely adopted technology recently developed. Many businesses are in the process of transitioning from standard 2D cell cultures to 3D cell cultures, which further help to enhance the analysis of a variety of diseases and illnesses. The most crucial stage is to analyze the processed and screened data, which require proper handling of the process to achieve the desired outcomes. The development of software and chemical libraries that can aid in the formation of best standards and reporting of results is a recent trend. While testing the natural environment and other cell-related alterations, 3D cells offer more effective features that can further assist medication design and discovery. Increasing the number of chemical libraries for proactive detection of chemical identity during testing and developing hardware and software to manage and fully automate the testing process are some key factors that are likely to boost the overall mark performance.
Systemic Toxicity segment is expected to dominate the market
On the basis of applications, the market is divided into systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and others. The systemic toxicity segment is expected to hold a key share of the market during the forecast period owing to the wide adoption of systemic toxicity tests for various healthcare applications. Since the most favored way of drug administration is through systemic circulation, it is also one of the most common causes of toxic responses. Meanwhile, the renal toxicity and hepatotoxicity segment in combined is expected expand steadily in the coming years. The segment growth can be attributed to wide active research and studies being conducted in these fields.
Cellular assay segment is anticipated to register at a substantial CAGR
Based on methods, the ADME toxicology testing market is divided into cellular assay, biochemical assay, in-silica, and ex-vivo. The cellular assay segment is expected to account for a key share of the market during the forecast period owing to the cell assay method which can yield highly detailed, accurate, and near-natural results. For drug candidates, cell-based physiological tests are seen as a bridge between the lab and the clinic. These tests do not necessarily replace clinical trials but they do make human research less risky and also keep the minimum number of animals used in experiments.
Asia Pacific is anticipated to dominate the market
On the basis of regions, the ADME toxicology testing market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of Asia Pacific is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to increasing research and development of new pharmaceutical compounds as well as the deployment of innovative technologies to improve the quality of medicine delivered. China and Japan are key countries holding major share of the market in the region. However, North America is expected to register a high CAGR during the forecast period owing to wide adoption of advanced technology in diagnostic procedures and continuous technical improvements in the healthcare industry especially in the US. Therapeutic development strategies based on cell cultures have become increasingly common among the regional-based companies attempting to bring a new drug compound to market. This is anticipated to boost the market growth in the region.
Segments
Segments Covered in the Report
The global ADME toxicology testing market has been segmented on the basis of
Technology
- Cell Culture
- High Throughput
- Molecular Imaging
- OMICS Technology
Applications
- Systemic Toxicity
- Renal Toxicity
- Hepatotoxicity
- Neurotoxicity
- Others
Methods
- Cellular Assay
- Biochemical Assay
- In-Silica
- Ex-vivo
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Accelrys Inc.
- Agilent Technologies, Inc.
- Albany Molecular Research Inc.
- Beckman Coulter Inc.
- Catalent Inc.
- Charles River Laboratories International Inc.
- AbbVie
- Actelion Pharmaceuticals
- Amgen
- Biocon
- BioMarin
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Cipla
Competitive Landscape
Key players competing in the ADME toxicology testing market include Accelrys Inc.; Agilent Technologies, Inc.; Albany Molecular Research Inc.; Beckman Coulter Inc.; Catalent Inc.; Charles River Laboratories International Inc.; AbbVie; Actelion Pharmaceuticals; Amgen; Biocon; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; and Cipla. Companies are conducting various experiments using precise toxicity testing methodologies to enhance commercialise of their product portfolio. They are also adopting various market strategies, which would significantly cut drug development costs and save time on failed medications.
Request For Customization
Enquiry Before Buying
Speak With Analyst
